Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities

Headache

Volumn 50, Issue 3, 2010, Pages 413-419

  Masruha, Marcelo R ^a,b   Lin, Jaime ^a   De Souza Vieira, Domingos S ^b   Minett, Thais S C ^a   Cipolla Neto, José ^c   Zukerman, Eliova ^b   Vilanova, Luiz C P ^a   Peres, Mario F P ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Comorbidities; Hypothalamus; Melatonin; Migraine; Pathophysiology

Indexed keywords

6 SULPHATOXYMELATONIN; MELATONIN; UNCLASSIFIED DRUG;

6 SULPHATOXYMELATONIN URINE LEVEL; ADULT; AGED; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CHALDER FATIGUE QUESTIONNAIRE; CHRONIC FATIGUE SYNDROME; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPWORTH SOMNOLENCE QUESTIONNAIRE; FEMALE; FIBROMYALGIA; HEADACHE; HORMONE RELEASE; HORMONE URINE LEVEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; STATE TRAIT ANXIETY INVENTORY; TRANSFORMED MIGRAINE; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; BIOLOGICAL MARKERS; COMORBIDITY; DEPRESSIVE DISORDER; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; MALE; MELATONIN; MIDDLE AGED; MIGRAINE DISORDERS; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; QUESTIONNAIRES; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 77749305248     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01547.x     Document Type: Article

References (35)

1. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994 10 (44 Suppl. 7 S4 S5.
2. Peres MF, Sanchez del Rio M, Seabra ML, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001 71 : 747 751.
3. Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006 15 : 367 375.
4. Kelman L. The premonitory symptoms (prodrome): A tertiary care study of 893 migraineurs. Headache. 2004 44 : 865 872. (Pubitemid 39362310)
5. Bojkowski CJ, Arendt J. Factors influencing urinary 6- sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects. Clin Endocrinol (Oxf). 1990 33 : 435 444.
6. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia. 2005 25 : 403 411.
7. Markey SP, Higa S, Shih M, Danforth DN, Tamarkin L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta. 1985 150 : 221 225.
8. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. Nocturnal plasma melatonin levels in migraine: A preliminary report. Headache. 1989 29 : 242 245. (Pubitemid 20346774)
9. Masruha MR, de Souza Vieira DS, Minett TS, et al. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008 9 : 221 224.
10. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004 24 (Suppl. 1 9 160.
11. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 26 : 742 746.
12. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993 37 : 147 153.
13. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 33 : 160 172.
14. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992 15 : 376 381.
15. Bieling PJ, Antony MM, Swinson RP. The State-Trait Anxiety Inventory, Trait version: Structure and content re-examined. Behav Res Ther. 1998 36 : 777 788.
16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 4 : 561 571.
17. Bojkowski CJ, Arendt J. Annual changes in 6-sulphatoxymelatonin excretion in man. Acta Endocrinol (Copenh). 1988 117 : 470 476.
18. Murialdo G, Fonzi S, Costelli P, et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia. 1994 14 : 205 209.
19. Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia. 1995 15 : 136 139 discussion 79.
20. Zurak N. Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. Cephalalgia. 1997 17 : 723 728.
21. Williams LM, Hannah LT, Hastings MH, Maywood ES. Melatonin receptors in the rat brain and pituitary. J Pineal Res. 1995 19 : 173 177.
22. Ganguly S, Coon SL, Klein DC. Control of melatonin synthesis in the mammalian pineal gland: The critical role of serotonin acetylation. Cell Tissue Res. 2002 309 : 127 137.
23. Carrillo-Vico A, Garcia-Maurino S, Calvo JR, Guerrero JM. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J. 2003 17 : 755 757.
24. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol. 1994 34 : 30 35.
25. Paparrigopoulos T. Melatonin response to atenolol administration in depression: Indication of beta-adrenoceptor dysfunction in a subtype of depression. Acta Psychiatr Scand. 2002 106 : 440 445.
26. Brown R, Kocsis JH, Caroff S, et al. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry. 1985 142 : 811 816.
27. Beck-Friis J, Kjellman BF, Aperia B, et al. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand. 1985 71 : 319 330.
28. Miles A, Philbrick DR. Melatonin and psychiatry. Biol Psychiatry. 1988 23 : 405 425.
29. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychopharmacol. 2002 17 : 239 247.
30. Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol. 1999 10 : 73 83.
31. Kopp C, Vogel E, Rettori MC, et al. Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacol Biochem Behav. 1999 64 : 131 136.
32. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001 86 : 4727 4730.
33. Wikner J, Hirsch U, Wetterberg L, Rojdmark S. Fibromyalgia - A syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf). 1998 49 : 179 183.
34. Press J, Phillip M, Neumann L, et al. Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol. 1998 25 : 551 555.
35. Webb SM. Fibromyalgia and melatonin: Are they related? Clin Endocrinol (Oxf). 1998 49 : 161 162.